Compare Nippon India Pharma Fund vs SBI Healthcare Opportunities Fund
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.82 | 1.94 |
NAV | ₹486.81 | ₹403.64 |
Fund Started | 10 May 2004 | 04 Jun 1999 |
Fund Size | ₹8264.71 Cr | ₹3989.42 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
3.0
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.82
1.94
NAV
₹486.81
₹403.64
Fund Started
10 May 2004
04 Jun 1999
Fund Size
₹8264.71 Cr
₹3989.42 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 15 days
1 Year | -1.49% | -3.88% |
3 Year | 20.10% | 22.21% |
5 Year | 14.06% | 14.98% |
1 Year
-1.49%
-3.88%
3 Year
20.10%
22.21%
5 Year
14.06%
14.98%
Equity | 97.37% | 96.59% |
Cash | 2.62% | 3.34% |
Equity
97.37%
96.59%
Cash
2.62%
3.34%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 13.02% |
Lupin Ltd. | 7.36% |
Divi's Laboratories Ltd. | 6.58% |
Cipla Ltd. | 6.39% |
Dr. Reddy's Laboratories Ltd. | 6.02% |
Apollo Hospitals Enterprise Ltd. | 5.53% |
Vijaya Diagnostic Centre Ltd. | 3.71% |
Medplus Health Services Ltd. | 3.54% |
Ajanta Pharma Ltd. | 3.21% |
Sai Life Sciences Ltd. | 2.81% |
Sun Pharmaceutical Industries Ltd. | 11.64% |
Divi's Laboratories Ltd. | 7.05% |
Max Healthcare Institute Ltd. | 5.24% |
Lupin Ltd. | 4.44% |
Laurus Labs Ltd. | 3.89% |
Torrent Pharmaceuticals Ltd. | 3.86% |
Acutaas Chemicals Ltd. | 3.85% |
Cipla Ltd. | 3.79% |
Lonza Group Ag | 3.63% |
Biocon Ltd. | 3.16% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 10 May 2004 | 04 Jun 1999 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
10 May 2004
04 Jun 1999